David Filgueiras-Rama1,2,3, Jasmina Vasilijevic4,5, Jose Jalife2,3,6, Sami F Noujaim7, Jose M Alfonso2, Jose A Nicolas-Avila2, Celia Gutierrez4, Noelia Zamarreño4, Andres Hidalgo2, Alejandro Bernabé2, Christopher Pablo Cop2, Daniela Ponce-Balbuena6, Guadalupe Guerrero-Serna6, Daniel Calle2,8, Manuel Desco2,8,9,10, Jesus Ruiz-Cabello5,11,12,13, Amelia Nieto4,5, Ana Falcon4,5. 1. Cardiac Electrophysiology Unit, Hospital Clínico San Carlos, Madrid, Spain. 2. Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain. 3. Consortium CIBER of Cardiovascular Diseases (CIBERCV), Spain. 4. Department of Molecular and Cellular Biology, National Center for Biotechnology, Spanish National Research Council, Madrid, Spain. 5. Consortium CIBER of Respiratory Diseases, Spain. 6. Center for Arrhythmia Research, Health System, University of Michigan, MI, USA. 7. Morsani College of Medicine Molecular Pharmacology & Physiology, University of South Florida, Tampa, FL, USA. 8. Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain. 9. Department of Bioengineering and Aerospace Engineering, University Carlos III of Madrid, Madrid, Spain. 10. Consortium CIBER of Mental Health (CIBERSAM), Spain. 11. Center for Cooperative Research in Biomaterials (CIC biomaGUNE), Basque Research and Technology Alliance (BRTA), San Sebastian, Spain. 12. IKERBASQUE, Basque Foundation for Science, Spain. 13. Universidad Complutense Madrid, Madrid, Spain.
Abstract
AIMS: Human influenza A virus (hIAV) infection is associated with important cardiovascular complications, although cardiac infection pathophysiology is poorly understood. We aimed to study the ability of hIAV of different pathogenicity to infect the mouse heart, and establish the relationship between the infective capacity and the associated in vivo, cellular and molecular alterations. METHODS AND RESULTS: We evaluated lung and heart viral titres in mice infected with either one of several hIAV strains inoculated intranasally. 3D reconstructions of infected cardiac tissue were used to identify viral proteins inside mouse cardiomyocytes, Purkinje cells, and cardiac vessels. Viral replication was measured in mouse cultured cardiomyocytes. Human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) were used to confirm infection and study underlying molecular alterations associated with the in vivo electrophysiological phenotype. Pathogenic and attenuated hIAV strains infected and replicated in cardiomyocytes, Purkinje cells, and hiPSC-CMs. The infection was also present in cardiac endothelial cells. Remarkably, lung viral titres did not statistically correlate with viral titres in the mouse heart. The highly pathogenic human recombinant virus PAmut showed faster replication, higher level of inflammatory cytokines in cardiac tissue and higher viral titres in cardiac HL-1 mouse cells and hiPSC-CMs compared with PB2mut-attenuated virus. Correspondingly, cardiac conduction alterations were especially pronounced in PAmut-infected mice, associated with high mortality rates, compared with PB2mut-infected animals. Consistently, connexin43 and NaV1.5 expression decreased acutely in hiPSC-CMs infected with PAmut virus. YEM1L protease also decreased more rapidly and to lower levels in PAmut-infected hiPSC-CMs compared with PB2mut-infected cells, consistent with mitochondrial dysfunction. Human IAV infection did not increase myocardial fibrosis at 4-day post-infection, although PAmut-infected mice showed an early increase in mRNAs expression of lysyl oxidase. CONCLUSION: Human IAV can infect the heart and cardiac-specific conduction system, which may contribute to cardiac complications and premature death.
AIMS: Human influenza A virus (hIAV) infection is associated with important cardiovascular complications, although cardiac infection pathophysiology is poorly understood. We aimed to study the ability of hIAV of different pathogenicity to infect the mouse heart, and establish the relationship between the infective capacity and the associated in vivo, cellular and molecular alterations. METHODS AND RESULTS: We evaluated lung and heart viral titres in mice infected with either one of several hIAV strains inoculated intranasally. 3D reconstructions of infected cardiac tissue were used to identify viral proteins inside mouse cardiomyocytes, Purkinje cells, and cardiac vessels. Viral replication was measured in mouse cultured cardiomyocytes. Human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) were used to confirm infection and study underlying molecular alterations associated with the in vivo electrophysiological phenotype. Pathogenic and attenuated hIAV strains infected and replicated in cardiomyocytes, Purkinje cells, and hiPSC-CMs. The infection was also present in cardiac endothelial cells. Remarkably, lung viral titres did not statistically correlate with viral titres in the mouse heart. The highly pathogenic human recombinant virus PAmut showed faster replication, higher level of inflammatory cytokines in cardiac tissue and higher viral titres in cardiac HL-1 mouse cells and hiPSC-CMs compared with PB2mut-attenuated virus. Correspondingly, cardiac conduction alterations were especially pronounced in PAmut-infected mice, associated with high mortality rates, compared with PB2mut-infected animals. Consistently, connexin43 and NaV1.5 expression decreased acutely in hiPSC-CMs infected with PAmut virus. YEM1L protease also decreased more rapidly and to lower levels in PAmut-infected hiPSC-CMs compared with PB2mut-infected cells, consistent with mitochondrial dysfunction. Human IAV infection did not increase myocardial fibrosis at 4-day post-infection, although PAmut-infected mice showed an early increase in mRNAs expression of lysyl oxidase. CONCLUSION: Human IAV can infect the heart and cardiac-specific conduction system, which may contribute to cardiac complications and premature death.
The influenza A virus (IAV) is a major contributor to acute respiratory infections, but its pathogenicity is not limited
to respiratory damage. Various complications in non-respiratory tissues (e.g.
encephalopathy) have been described during seasonal influenza infections,, Among others, myocarditis and congestive heart
failure have been associated with IAV infection, Focal-to-diffuse myocarditis has been reported during the Asian and
1918 influenza pandemics. More
recently, during the 2009 pandemic, cardiac complications have been described in 4.9% of
hospitalized patients, and up to 46% of patients admitted to intensive care units. Current evidence also indicates
that, in patients with pre-existing atherosclerotic disease, pulmonary infection induces an
inflammatory response that may trigger an acute coronary syndrome. Moreover, severe ventricular arrhythmia with fatal
consequences and high-degree atrio-ventricular block have been also reported in infected
patients, even without apparent respiratory damage.,Despite potential IAV-related cardiac damage after infection, the rare reports showing
viral material in the human myocardium remain unconfirmed. Moreover, human IAV pathophysiology in cardiac
tissue and the associated in vivo, cellular and molecular alterations
remain unexplored. Thus, current understanding mostly assumes that cardiac pathology on
human IAV infection is directly related to respiratory tract damage and a subsequent
inflammatory reaction that may lead to cardiac complications in patients with significant
comorbidities.,Importantly, during the process of identifying the pathogenicity factor of a lethal
influenza A virus (F-IAV) isolated from the 2009 pandemic, we generated recombinant viruses carrying mutations
in PA and PB2 viral polymerase subunits of F-IAV on the A/H1N1/California/04/09 virus
backbone (CAL). The use of a
recombinant virus carrying PA D529N (PAmut) showed that this mutation was responsible for
the augmented pathogenicity of the F-IAV isolate, while a recombinant virus with the
mutation PB2 A221T (PB2mut) was attenuated in mice. Here, we hypothesize that human IAV can also infect and replicate
in the mouse heart and cultured cardiomyocytes. Moreover, cardiac damage and underlying
molecular alterations will be directly associated with virus pathogenicity, although cardiac
infection and viral titres in heart tissue will not necessarily follow a direct relationship
with lung titres. We tested this hypothesis using pathogenic PAmut and attenuated PB2mut
recombinant viruses to explore the ability of human IAV to infect and trigger cardiac damage
in infected mice in vivo, heart tissue samples and cultured cardiomyocytes.
We also studied the underlying molecular alterations associated with the in
vivo virus-related electrophysiological phenotype using infected human-induced
pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs). Altogether, our data report direct
cardiac infection and heart damage related to human IAV pathogenicity and not necessarily
related to lung viral titres, which may contribute to the severity or even fatality of
influenza virus infections in humans.
2. Methods
The in vivo studies were conducted in accordance with institutional
guidelines and National, European, and US National Institute of Health guidelines for the
care and use of laboratory animals. Protocols were approved by the National Center for
Biotechnology Ethics Committee on Animal Experimentation (permit no. 11014) and
Institutional Animal Care and Use Committee of the University of Michigan (approval no.
PRO0006827). Animals were anesthetized with isoflurane (3%) in an inhalation chamber before
viral inoculation. Animals were euthanized with isoflurane (7%) inhalation followed by a
second euthanasia method (bilateral pneumothorax or removal of vital organs, lungs and/or
heart as indicated). Figure
shows a flowchart with all the experimental sets.Flowchart showing all the experimental sets. C-MRI, cardiac magnetic resonance imaging;
dpi, days post-infection; ECG, electrocardiogram; FA, formaldehyde treatment; hpi, hours
post-infection; LV, left ventricle; n, number of inoculated animals;
N, total number of animals in each experimental set;
n, number of animals in each group; PFU, plaque-forming units; RV,
right ventricle.
2.1 Biological materials
Cell lines used in this study were MDCK (canine kidney; ATCC CCL-34), and cardiac HL-1
(mouse). Human-induced PSC-CMs were derived from iCell™ cardiomyocytes obtained from
Cellular Dynamics International (Madison, WI) using a modified protocol previously
described elsewhere (more
details in Supplementary material
online). Briefly, the iCell™ cardiomyocytes were thawed and plated in
differentiation medium (EB20), and 24 h later, medium was switched to RPMI plus B27
supplement with insulin (Gibco). Antibodies to GAPDH, β-actin (both from Sigma), and
rabbit anti-NP–PB1 antibodies were used for western blot., Western-blot assays were performed as described
elsewhere.
2.2 Cell infection
Cultured mouse HL-1 cells were infected at 10−3 or 3–5 plaque-forming units
(pfu)/cell as indicated in each experiment. Cells were used for western-blot and
immunofluorescence analyses, and supernatants were used for virus titration by standard
plaque assay. Human iPSC-CM
cultures were Mock-infected or infected with PAmut or PB2mut recombinants at 3
multiplicity of infection (moi).
2.3 Mice with Connexin40 and green-fluorescent protein (Cx40eGFP)
We used Cx40eGFP mice to enable visualization of the Purkinje network via GFP
expression. Founders for our Cx40eGFP mouse colony were generously provided by
the laboratory of Dr Daniel Gros at Université de la Méditerranée, Marseille, France.
Generation and characterization of these transgenic mice have been described in detail
previously. Briefly, these
mice were generated by insertion of the eGFP coding sequence into the
GJA5 gene locus by homologous recombination, and were maintained under
a mixed genetic background (CD1/129 Sv). Heterozygous offspring were intercrossed to
obtain homozygously mutated progeny, as described elsewhere.
2.4 In vivo virus infections in mice
All animal studies were performed under biosafety level 2+ conditions. Female BALB/c
AnNHsd mice (6 weeks old) were infected intranasally with the corresponding recombinant
viruses at 106 or 103 plaque-forming units (pfu) as indicated in
each experiment or were Mock-infected. Female Cx40eGFP mice (7 weeks old) were
also infected intranasally with PAmut or PB2mut viruses at 106 pfu, or were
Mock-infected. All animals were monitored daily for body weight. For ethical reasons, in
all experiments, mice were euthanized when a 25% body weight loss was documented. Total
heart or lung extracts were used for viral titre determination by plaque assay,
biochemical analysis, or confocal immunofluorescence as described below.
2.5 Immunostaining and confocal microscopy of cardiac tissue and cultured
cells
Mock, PAmut-, and PB2mut-infected HL-1 cells were collected at specified hours
post-infection (hpi), fixed with methanol for 20 min at −20°C and stored in
phosphate-buffered saline. Cells were incubated with a primary rabbit anti-NP
antibody and subsequently
incubated with a secondary Alexa 594-conjugated goat anti-rabbit antibody (Molecular
Probes, Eugene, Oregon).Mock, PAmut-, and PB2mut-infected mouse hearts were collected, fixed in 15% formalin, and
embedded in paraffin [for wild-type (WT) hearts] or optimum cutting temperature compound
(for Cx40eGFP hearts). About 8- to 10 µm slices were obtained using a
microtome. Prior to use, paraffin samples were deparaffinized and hydrated. Epitope
unmasking was performed using DAKO target retrieval solution (Ref. S1699) in a PTlink
equipment (DAKO). The samples were used for confocal microscopy using DAPI, and the
following primary antibodies: rabbit anti-NP, rat anti-NP, and rabbit anti-laminin (polyclonal; Sigma); and
secondary antibodies: chicken anti-rat AF647 and goat anti-rabbit AF488/AF546 (Molecular
Probes, Eugen, Oregon).AQ7 All images were obtained using an SPE confocal microscope
(Leica). The NP+ area was calculated using a threshold based on absolute intensity and
automatic quantification with FIJI (National Institutes of Health, USA).
2.6 Histopathology analysis
Ventricular cross-sections from both WT and Cx40eGFP mice were dehydrated and
cut into 10-µm thick sections. Haematoxylin and eosin (H&E) stained sections were
digitized using a NanoZoomer S360 Digital slide scanner (Hamamatsu, Japan) for subsequent
analysis. Sequential analysis of stained samples was performed to identify any regions
with overt conventional histopathologic features of coagulative necrosis, including
elongated and pyknotic nuclei, loss of the striated cardiomyocyte structure, slight
increases in colour intensity, and glassy cytoplasm.Tissue slices were also stained with Masson Trichrome and digitized using a NanoZoomer
S360 Digital slide scanner (Hamamatsu, Japan) for analysis. A total of five randomly
selected 20× insets per slide were analysed. Interstitial fibrosis was quantified using
ImageJ. Colour threshold hue (scale: 0–255) was adjusted for each image to include only
blue pixels (scale: 115–210), corresponding to collagen fibres, and the values for each
area were recorded. Fibrosis proportion (blue staining areas/total tissue area) was
measured in every inset and a mean value was assigned to each sample.
2.7 ATP quantification
ATP content was assessed by ATP Bioluminescence Assay Kit CLS II (Roche, Mannheim,
Germany) according to the manufacturer’s instructions.
2.8 3D reconstructions of viral protein in cardiac tissue
3D localization of viral particles was performed using the Imaris Software (Bitplane AG,
Switzerland). For 3D reconstructions, we used a 0.20-µm detail level and a threshold based
on absolute intensity. All images were reconstructed from a 5–10 µm depth stacked
image.
2.9 RNA extraction and PCR
RNA was isolated from myocardial samples of Mock, PAmut-, and PB2mut-infected mouse
hearts using TRIzol (15596026, Thermo Fisher Scientific). cDNA was then synthesized from
total RNA using the Applied Biosystems High Capacity cDNA Reverse Transcription kit
(4368814, Thermo Fisher Scientific). Gene expression analysis in cardiac tissue was
performed by quantitative PCR (qPCR). Then qPCR was conducted with SYBR Green (4367659,
Thermo Fisher Scientific), and cDNA was amplified using DNA primers designed for every gen
based on the mouse genome. Gene expression of interleukin (IL)-1ß, IL-6, lysyl oxidase,
and brain natriuretic peptide were evaluated. Housekeeping genes (GAPDH and B2M) were
measured for gene expression normalization and the 2−ΔΔCt method was used for
relative gene expression quantification.Specific primers to amplify viral NEP mRNA were designed to detect it by PCR. NEP mRNA is
a spliced mRNA transcribed from the NS viral segment that is only present in cells with
ongoing viral replication and transcription.
2.10 Surface ECG analysis of mice infected with influenza virus
Three groups of WT conscious mice including 10 animals per group (Mock, PB2mut, and
PAmut) were used to study any potential ECG alterations during sequential follow-up
(Figure ). ECGs were
recorded in the fully awake state to circumvent any potential anaesthesia-related
confounding factor associated with ventilation problems. Upon inoculation (Day 0), ECG
changes in conventional intervals (PR segment, QRS complex, and QT interval) were
monitored daily. Three animals were euthanized on Day 1 after inoculation, two animals on
Day 2, and two animals on Day 4 to obtain ventricular samples for monitoring viral titre,
western-blot, immunohistochemistry, and qPCR analyses. The remaining three animals per
group at Day 4 after inoculation were used for cardiac magnetic resonance imaging (C-MRI)
studies after completing the sequential follow-up of ECG parameters. Data were stored for
off-line analysis using custom MatLab scripts for pre-processing, visualization, and
quantification of electrophysiological intervals and heart rate variability (see Supplementary material online,
).
Further technical details are described in the Supplementary material online.
2.11 High-resolution cardiac magnetic resonance imaging
Nine explanted mouse hearts underwent C-MRI characterization of any overt and
virus-related short-term structural damage. Four days after virus inoculation, three
animals from each experimental group were euthanized after completing the last ECG
follow-up (Figure ). Five
minutes before euthanasia and heart removal, a 0.2 mM/kg bolus of gadolinium-based
contrast agent (Gadovist, Bayer Hispania, S.L.) was injected intravenously to ensure that
gadolinium reached the whole heart. All explanted and preserved hearts underwent C-MRI
using a 7-T Agilent/Varian scanner (Agilent, Santa Clara, CA, USA) equipped with a DD2
console and an actively shielded 115/60 gradient with a homemade solenoidal small coil for
microimaging. The imaging protocol consisted of a 3D image (spin echo sequence, voxel
resolution 31.3×70.3×31.3 µm) followed by a T1 map (inversion recovery spin echo
multi-slice sequence, six slices, slice thickness: 0.5 mm). Further technical details are
described in the Supplementary material
online, .
2.12 Statistical analyses
Student’s t-test, two-way ANOVA, χ2, or the non-parametric
Kruskal–Wallis test for multiple comparisons were applied as appropriate. A
P < 0.05 was considered statistically significant. All data were
analysed with GraphPad Prims v.5.00 (GraphPad Software Inc., CA, USA).
3. Results
3.1 Mice infected with influenza virus die prematurely
We previously identified a higher mortality rate for PAmut virus compared to PB2mut, CAL,
and double mutant PB2/PAmut recombinant viruses. During the determination of the 50% lethal dose (infection with
103, 104, 105, 106 pfu) of these recombinant
viruses, we observed that mortality of mice infected with PAmut and PB2/PAmut (dose
106 pfu) occurred before reaching 75% of the original body weight that
constitutes the ethical limit established for euthanasia (range: 95–77% of the original
weight; Figure ). The data
indicate that these recombinant viruses may cause premature death in some infected
animals.Premature death upon influenza A virus (IAV) infection correlates with high levels of
infectious particles, active viral replication, and the presence of spliced viral NEP
mRNA in the heart. BALB/c AnNHsd mice (n = 4) were intranasally
infected with 106 pfu of the indicated viruses. (A) Body
weights represented as percentage of body weight at inoculation (time 0). Red numbers
denote body weight of animals with premature death. The experiment was performed twice
and the results were similar. (B) BALB/c AnNHsd mice
(n = 5) were intranasally infected with 103 pfu with the
indicated viruses. Prevalence of IAV in the heart of infected animals shown as
percentage of total animals. (C) Correlation of heart viral titres in
each IAV-infected mouse with lung viral titres at different days post-infection (dpi).
NA, not applicable, all values below detection limit in the heart.
(D) Scheme of influenza virus spliced NEP mRNA and NS1 mRNA collinear
to full-length NS segment. Red and green arrows indicate localization of primers used
in PCR to detect NEP mRNA. (E) Sequence of the spliced NEP mRNA
sequence (grey) within the full-length viral NS segment sequence. Red and green
rectangles represent the sequence of forward and reverse primers used for
amplification of spliced NEP mRNA, respectively. (F) Agarose gel with
amplified NEP mRNA in heart samples of CAL-, PB2mut-, PAmut-, or PB2/PAmut-infected
mice obtained at 2 dpi (at time of the highest viral titres in panel
D). + indicates samples showing infectious viral particles. −
indicates samples not showing infectious viral particles as determined by plaque assay
(B and C). Arrow bands corresponding to spliced NEP mRNA. The
asterisk indicates dimer primers. (G) Sequence of the obtained
amplicons.
3.2 Human recombinant viruses are present in the hearts of infected mice
Mice infected with a previously described F-IAV virus, associated with a fatal case
infection, showed certain amount of infectious particles in their heart. These data, together with
premature death documented in PAmut and PB2/PAmut-infected mice, prompted us to study the
ability of human influenza virus to infect the heart. We explored the presence of IAV in
hearts of mice infected with a sub-lethal dose (103 pfu) of mutant virus and
tested for heart viral titres compared with lung viral titres in each infected animal. At
2 dpi, we found viral particles in the heart of a high proportion of all infected mice
(Figure ), but the
frequency and duration of infection were higher in PAmut-infected mice. Lung viral titres
progressively increased after inoculation in all infected mice and reached the highest
values at 2 dpi (Figure ).
Lung viral titres also showed that mice infected with PAmut or PB2/PAmut had the highest
viral titres at all time intervals. Accordingly, cardiac viral titres were detected earlier in
PAmut-infected mice (Figure ) and remained for longer time during the 4-day follow-up period.
Importantly, lung viral titres obtained with any of the recombinant viruses did not
statistically correlate with viral titres in the mouse heart at any of the time intervals
(Figure , shown
r2). Thus, similar lung viral titres showed a wide range of
heart viral titres (in Figure , see red and orange dots at 2 dpi and black and red dots at 4 dpi).
The latter supports the notion that heart infection does not directly correlate with the
extension of lung infection, and virus pathogenicity may be a more relevant factor to
reach and infect the heart in vivo.
3.3 Influenza virus replication is present in infected hearts
The spliced viral NEP mRNA (a product of replication, Figure ) was detected in all infected hearts (‘+’
samples in Figure ) and
was absent in heart samples of infected animals without heart infection (‘−’ samples in
Figure ). Furthermore,
the viral NP protein was found in the nucleus and cytoplasm of cardiomyocytes from
infected hearts (Figure and see Supplementary
material online, and Videos S1 and S2). Moreover,
quantification of the NP signal in infected ventricular tissue showed significantly higher
values in PAmut-infected hearts compared with PB2- and Mock-infected hearts
(Figure ). This is
consistent with higher viral titres in PAmut-infected hearts (Figure ). Further analysis of infected
hearts also detected NP signal in cardiac endothelial cells (Figure ). These data demonstrate that human
IAV can replicate in the heart of infected mice. Furthermore, virus pathogenicity and
infection of the endothelial cells of blood vessels seem to be involved in viral spread
from lung tissue to the heart.Active replication of influenza A virus in cardiac tissue. PAmut virus replicates
faster than attenuated PB2mut virus in HL-1 cells. (A) Detection of
viral nucleoprotein (NP) by confocal microscopy of immunofluorescences in heart tissue
from control animals (MOCK; upper panels, a–d), PAmut virus- (middle
panels, e–i) or PB2mut virus- (lower panels, j–n)
infected animals. The boxed areas in merged images (h and
m) are shown enlarged in the insets (i and
n). (B) 3D reconstructions of cytoplasmic (left
panel) or nuclear (right panel) NP viral protein in PAmut-infected heart tissue (see
Supplementary material
online, Videos S1 and S2). Magenta, auto-fluorescence in
cardiomyocytes; NP viral protein is showed in white for better visualization in 3D
reconstructions. (C) Quantification of NP signal in infected heart
tissues at 2-day post-infection (dpi). A minimum of 27 images from two different
hearts have been quantified for each group. *P < 0.05 by Student’s
t-test. (D) Detection of viral NP in endothelial
cells surrounding a heart blood vessel from animals infected with PAmut virus.
(E) Viral replication kinetics of control CAL, PAmut, or PB2mut
virus in cultured HL-1-infected cells (10−3 multiplicity of infection,
moi). Experiments were performed in triplicates. Significance was determined by
two-way ANOVA with Bonferroni post hoc test (*P < 0.05;
**P < 0.01; ***P < 0.001).
(F) At indicated hours post-infection (hpi), samples of Mock-,
PB2mut- or PAmut-infected HL-1 cells (moi 5) were used for immunofluorescence confocal
microscopy. Arrows and arrowheads indicate nuclear and cytoplasmic localization of NP
protein, respectively. Experiments were performed in triplicates. (G)
Distribution of nuclear, cytoplasmic, or both localizations of NP viral protein within
100% of positive PB2mut- or PAmut-infected cells at 8 hpi (top) and 12 hpi (bottom). A
minimum of 160 cells from three independent experiments were analysed for PB2mut or
PAmut virus at each time point. Significance was determined by χ2 test (***
P < 0.001). Blue, nucleus staining (DAPI); green, laminin; red,
NP viral protein (but white, C).
3.4 Viral pathogenicity determines viral replication kinetics in cardiac
cells
Direct cardiac pathogenicity and replication, independent of lung infection, was
addressed using infected mouse HL-1 cardiac muscle cells with PAmut or PB2mut
recombinants; or with CAL recombinant as control virus. Infection at low moi (0.001)
showed significantly faster-growing kinetics and higher viral titres in PAmut-infected
cells compared to PB2mut- or CAL-infected cells (Figure ). Interestingly, such differences were not present
in lung epithelial cells infected with either PAmut or PB2mut virus (see Supplementary material online,
). Cells
were also infected at high moi (3) with PAmut or PB2mut viruses, or were Mock-infected as
control. PAmut-infected cells accumulated significantly higher levels of viral NP and PB1
proteins than attenuated PB2mut-infected cells (see Supplementary material online,
).
Differences in viral kinetics were also monitored by nuclear (early infection) or
cytoplasmic (late infection) localization of NP in cells infected at 5 moi using confocal
immunofluorescence microscopy (Figure ). At 8 hpi, NP was mainly detected in the nucleus of
PB2mut-infected cells and in the cytoplasm of PAmut-infected cells. Quantitative analysis
showed that NP distribution was significantly different between PB2mut and PAmut viruses
(Figure ). Altogether,
the data demonstrate that human IAV can infect and replicate in cardiac cells with
replication kinetics directly related to virus pathogenicity.
3.5 Viral pathogenicity determines early inflammation and imbalance in extracellular
matrix of infected hearts
Heart samples from PAmut-, PB2mut-, and control Mock-infected mice did not reveal any
overt acute histopathologic alterations in H&E stained samples (Figure ). Masson Trichrome staining of
heart tissue did not reveal any significant increase in cardiac fibrosis with any of the
recombinant viruses at 4 days after inoculation (Figure ). Consistent with histopathology analyses,
neither post-contrast T1 mapping data nor the normalized fibrosis volumes was
significantly different among Mock-, PB2mut-, and PAmut-infected mice (see Supplementary material online,
).
Cardiac MRI-derived myocardial mass quantification was similar in infected and Mock
control animals. Representative sample cases are shown in Figures S3 and
S4, see Supplementary
material online.Histopathology and tissue changes in infected mice. (A)
Representative heart samples of H&E staining in the three groups of infected mice.
(B) Representative heart samples of Masson Trichrome staining from
the three groups of infected mice. (C) Fibrosis quantification in
heart samples obtained 4 days after infection (n = 3).
(D–G) mRNA quantification and statistical comparisons of lysil
oxidase (LOX) (D), BNP (E), IL-1ß
(F), and IL-6 (G) among Mock
(n = 4), PA mut (n = 6) and PB2mut
(n = 7) groups of infected mice. Significance was determined by
two-way ANOVA (*P < 0.05; **P < 0.01). BNP,
brain natriuretic peptide.More specific analyses using qPCR revealed an early and statistically significant
increase of lysyl oxidase mRNA in cardiac samples from mice infected with the highly
pathogenic PAmut virus (Figure ). Although sequential echocardiography studies were not performed
because of biosafety restrictions, Brain Natriuretic Peptide (BNP) mRNA did not
significantly increase in any of the infected groups of animals (Figure ). Conversely, an acute
pro-inflammatory response was detected in the heart of PAmut- and PB2-infected mice. More
specifically, IL-1ß mRNA levels significantly increased in PAmut- and PB2-infected mice
compared to Mock-infected controls (Figure ). IL-6 mRNA only increased significantly in mice infected with the
most pathogenic PAmut virus (Figure ).
3.6 Influenza virus-infected mice show significant cardiac conduction
alterations
Mice were infected with 106 pfu (dose associated with premature death in
PAmut-infected animals; Figure ). A total of 51 820 heartbeats were included for analysis using an
average of 460 ± 92 beats per ECG acquisition during the 4-day sequential follow-up.
PAmut- and PB2mut-infected mice developed progressively longer RR intervals than controls
(Figure ). The
maximum effect of PAmut and PB2mut infection on RR intervals was observed at 2 dpi
(Figure ).
PAmut-infected mice also showed significantly longer RR intervals than PB2mut-infected
mice at 2 dpi (Figure ).
The PR interval also showed significantly longer values in PAmut- and PB2mut-infected mice
at 2 dpi compared to baseline values (Figure ). QRS complex duration was significantly prolonged in
PAmut-infected mice compared to controls at 2 dpi (Figure ). Corrected QT intervals were similar among groups
(Figure ). Parallel to
ECG alterations (see Supplementary
material online, ) and indicative of disease, body weight loss was substantially
higher in PAmut- and PB2mut-infected mice compared to controls (see Supplementary material online,
). Mortality rates were also significantly higher in PAmut-infected
mice compared to PB2mut-infected animals and controls (see Supplementary material online,
). In the same animals, further molecular analyses showed that ATP
levels in PAmut-infected mice significantly decreased compared to Mock- and
PB2mut-infected mice (Figure ). Moreover, decreased ATP levels inversely correlated with viral
titres in heart samples of those animals (Figure ), which further reflects the higher pathogenicity
of the recombinant PAmut virus. Daily ECG recordings demonstrated that severe cardiac
conduction alterations could be present at the time of premature death. This may happen in
the absence of histopathologic features of coagulative necrosis or a significant increase
in fibrosis, as shown in the representative case of Figure .ECG alterations in mice infected with influenza virus. (A) Randomly
selected tracings from control, PB2mut, and PAmut mice at Days 0 and 2 after virus
inoculation. The tracings show overt prolongation of RR intervals (slower heart rate)
and PR intervals in PAmut-infected mice at Day 2. Blue asterisks indicate R waves.
(B–E) Surface ECG-based quantification of cardiac rhythm and
conduction alterations in virus-infected animals and control mice. *, #, †, and ‡ show
P < 0.05 for PAmut vs. PAmut Day0 (*), PB2mut vs. PB2mut Day0
(#), PAmut vs. controls at that time point (†), and PB2mut vs. controls at that time
point (‡). Animals (n = 10) were intranasally infected with
106 pfu of PB2mut, or PAmut recombinant virus or were Mock-infected, and
were sequentially euthanized for collection of samples . Number of animals for
comparisons: Days 0, 1: n = 10 (PB2 and PA) and
n = 9 (Mock. The 10th animal was excluded due to poor signal
quality); Day 2: n = 7 per group; Day 3: n = 5 per
group; and Day 4: n = 5 (PB2, Mock) and n = 4 (PA.
The fifth animal died on Day 3). Significance was determined by two-way
repeated-measures ANOVA with Bonferroni post hoc test (*P < 0.05;
**P < 0.01). (F) ATP levels were evaluated in
triplicates in total heart extracts at 1- (n = 3), 2-
(n = 2), and 4- (n = 2) day post-infection (dpi).
Mock data are shown as 100% in one dot. (G) Viral titres were
determined in hearts of the same infected animals at indicated dpi and were evaluated
in duplicates (1 dpi, n = 3; 2 dpi, n = 2; 4 dpi,
n = 2, per group). In (F) and
(G), significance was determined by Student’s t-test
(ns: not significant, *P < 0.05, **P < 0.01).
(H) Representative ECG alterations in a PAmut-infected mouse before
dead. Haematoxylin and eosin (H&E) and Masson trichrome staining from the same
animal.
3.7 Infected animals show active viral replication in cardiac Purkinje cells
Influenza virus infection of cardiac-specific Purkinje cells may further contribute to
ECG alterations in vivo. Immunofluorescence and confocal microscopy
analyses in excised hearts (see Supplementary material online, ) from PAmut- and PB2mut-infected
Cx40eGFP transgenic mice identified the NP protein in both the cytoplasm and
the nucleus of Purkinje cells (Figure and see Supplementary material online, Videos S3 and S4). This
indicates also active viral replication in the cardiac-specific conduction system. As
reported in infected WT animals, histopathology analysis did not show overt relevant
alterations in H&E and Masson Trichrome (n = 3 per group, median
fibrosis: 0.03%, 0.04%, and 0.01% for Mock-, PB2mut- and PAmut-infected animals,
respectively) stained samples (Figure ).Active replication of influenza A virus in Purkinje cells. (A)
Detection of the NP viral protein using immunofluorescence confocal microscopy in
heart tissue from Cx40eGFP MOCK-infected mice (upper panels,
a–c) and animals infected with 106 pfu of either PAmut
virus (middle panels, d–f) or PB2mut virus (lower panels,
g–i). Right panels (j–k) show 3D reconstructions
of the NP viral protein in Purkinje cells of PAmut- (j) or
PB2mut-infected hearts (k) from Cx40eGFP animals (see also
Supplementary material
online, Videos S3 and S4). Blue, nuclear staining (DAPI);
green, GFP; red, laminin; white, NP viral protein staining. (B and
C) H&E staining (B) and Masson Trichrome
staining (C) of representative heart samples from
Cx40eGFP-infected mice.
3.8 Human-induced pluripotent stem cell-derived cardiomyocytes as a model for human
heart infection
Consistent with the data obtained in HL-1 cardiac cells and in the mouse heart, hiPSC-CMs
were also susceptible to human IAV infection. At 12 hpi, after 3 moi infection, viral PB1
accumulation levels were significantly higher in PAmut-infected cells than in attenuated
PB2mut-infected ones (Figure ). Moreover, YMLE1 protease, an indicator of mitochondrial integrity,, significantly decreased in infected cells. The
latter was also more exacerbated in PAmut-infected cells compared to PB2mut-infected ones
(Figure ). This
was also consistent with the decrease in ATP levels documented in infected mice hearts
(Figure ). Further
analysis of the underlying causes associated with the electrophysiological phenotype
in vivo showed that Kir2.1 levels did not significantly change among
the infected groups (Figure ), consistent with non-significant changes in the QT interval in
vivo (Figure ).
Conversely, Cx43 and NaV1.5 levels decreased in influenza virus-infected cells, especially
in the highly pathogenic PAmut infection (Figure ), which was also consistent with QRS
complex prolongation in vivo (Figure ).Influenza A virus replication and electrophysiological phenotype of infected
hiPSC-CMs. hiPSC-CMs were Mock-infected or infected with the indicated virus (3 moi)
Samples were used to detect the indicated proteins by western blot at the specified
hours post-infection (hpi). (A) Viral PB1 protein.
(C) Mitochondrial protease YMEL1. (E) Kir2.1 and
NaV1.5 ion channels and Connexin43. GAPDH or α-actinin were used as loading control
and healthy human ventricle tissue (H—ventricle) was loaded as human
ion channels and Connexin43 control. MW denotes molecular weight markers. The
experiment was performed in triplicates (duplicates for YMEL1); one representative
sample is shown. Mock data are shown as 100% in one dot. B,
D, F, G, and H
indicate protein quantification and statistically significant analysis
(*P < 0.05, **P < 0.01,
***P < 0.001 by the Student’s t-test). moi,
multiplicity of infection.
4. Discussion
We report that both pathogenic and attenuated human IAVs can infect cardiomyocytes and
Purkinje cells in the mouse heart without correlation with lung viral titres. The infection
was also present in cardiac endothelial cells, which represent a potential pathway for viral
transmission from lung to heart tissue. The highly pathogenic recombinant PAmut virus
replicates more rapidly in mouse cardiomyocyte cultures and induces an early increase in
inflammatory cytokines with overt signs of bradycardia and abnormal cardiac impulse
propagation in vivo that may lead to premature death. The
electrophysiological phenotype in vivo was associated with an acute
decrease in Cx43 and NaV1.5 levels, and overt mitochondrial dysfunction in
infected hiPSC-CMs. The results indicate that direct heart infection may have important
implications in human influenza virus outbreaks, in addition to the indirect effects derived
from respiratory pathology. The latter is consistent with clinical reports of severe cardiac
complications in infected patients, even without apparent respiratory damage.,Multiple reports have indicated a temporal relationship of influenza outbreaks with acute
coronary events and increased mortality in the elderly.,, Recently, Kwong et al. have documented an increased incidence of acute
myocardial infarction within 7 days after detection of IAV infection. In fact, during
influenza epidemics, people with cardiovascular disease are particularly at risk of events,
and annual influenza virus immunization is currently recommended in adults with
cardiovascular disease.
Moreover, clinical evidence indicates that influenza vaccination may protect against acute
myocardial infarction.,Despite the association between influenza virus infection and cardiovascular events,
influenza virus antigens or RNAs have only rarely been noticed in the myocardium. Viral RNA
was detected in a myocardial biopsy of a young woman with fulminant myocarditis and
cardiogenic shock. Viral
antigens have been also detected in cardiomyocytes from another patient with fulminant
myocarditis. Endomyocardial
biopsies in a large series of patients with myocarditis have identified IAV RNA in five
patients. These clinical data
and more dramatic reports describing the association between IAV infection and sudden
cardiac death suggest that rather than a non-pathogenic viral RNA detection, concomitant to
pulmonary infection, IAV identification in the myocardium may represent a highly pathogenic
scenario that may determine clinical outcomes.,, A recent report by Kenney et al. have shown that influenza virus
replication in the heart and virus-related mortality dramatically increased in knockout mice
with antiviral restriction factor IFN-induced transmembrane protein 3 (IFITM3)
deficiency. These authors used a mouse-adapted influenza virus strain
that caused cardiac rhythm alterations and early activation of profibrotic and inflammatory
pathways. Our results provide new evidence of IAV virus replication in heart tissue using
human recombinant viruses carrying highly pathogenic (PAmut) and attenuated (PB2mut)
mutations present in a virus isolated from a fatal-patient case infected during the 2009
pandemic. Moreover, our data
show that heart infection and viral titres do not correlate with lung viral titres, which
supports the notion that rather than a consequence of respiratory damage, cardiac
complications may also relate to virus pathogenicity and independent replication in the
myocardium and specific cardiac conduction systems.The higher pathogenicity of the recombinant PAmut virus may be related to the fact that
this virus accumulates low amounts of defective viral genomes, which induces a lower
antiviral response in cultured cells and a higher lung inflammation compared with the
PB2mut. Interestingly, such a
reduced activation of the antiviral state might imply a delay in the immune response of
infected animals, which may enable the virus to grow and disseminate uncontrolled for a
short time, sufficient to infect the heart tissue. Consistent with such a hypothesis, we
found infectious particles in 100% of the hearts from PAmut-infected mice at 1 dpi
(Figure ). The
deficiency in the antiviral restriction factor IFITM3, recently associated with enhanced
pathogenesis and viral replication in the heart of infected mice, reinforce the antiviral response-related
pathogenicity of the PAmut virus. Moreover, the recombinant PAmut virus replicated faster
than the PB2mut in cardiac cultured cells, and generated larger ECG alterations and acute
mitochondrial dysfunction compared with the attenuated PB2mut. Altogether the data indicate
that the specific PA D529N mutation, present in a human fatal case virus, provides an
advantage for virus dissemination and replication in the myocardium. Therefore, it seems
reasonable that, rather than being an indirect consequence of respiratory damage upon
infection with highly pathogenic IAVs, a delay in the early immune response facilitates
direct cardiac infection and early myocardial damage.Possible explanations for the scarce detection of viral determinants in cardiac tissue of
infected patients could be a low capability of the majority of influenza virus strains to
infect cardiac cells and/or low levels of viral replication in heart tissue. Upregulation of
specific proteases capable of cleaving influenza virus HA in the mouse heart and in H9c2 rat
cardiomyocytes has been associated with the capacity of IAVs to propagate in the heart. Here, we demonstrate the ability of
human H1N1 IAV to infect and replicate in heart tissue of infected mice, HL-1 cardiac cells
and hiPSC-CMs. Although all the tested recombinant viruses infected the heart
(Figure ), including the
attenuated virus PB2mut, differences in pathogenicity correlated with cardiac virus
infection capacity and replication. ECG alterations and underlying molecular changes
(Figures ) were also consistent with virus pathogenicity.
Interestingly, IAV infection of HL-1 cells showed significantly faster-growing kinetics and
higher viral titres in PAmut-infected cells compared to PB2mut- or control WT CAL-infected
cells. However, such differences were not present in lung epithelial cells (see Supplementary material online,
),
which highlights the relevance of virus pathogenicity to replicate in cardiac tissue.The in vivo mouse electrophysiological phenotype showed that PAmut- and
PB2mut-infected mice developed acute progressive bradycardia. Bradycardia has been also
reported by Kenney et al. using a mouse-adapted influenza virus strain. Here, we also report
that the most pathogenic strain (i.e. PAmut) significantly affected the PR interval and QRS
complex duration. Interestingly, conduction abnormalities and high-degree atrio-ventricular
block have been documented also in human cases of myocarditis associated with influenza A
virus infection. In addition,
and early inflammatory state was also present in the heart of infected mice. Moreover, ECG
alterations and pro-inflammatory cytokines were consistent with higher viral titres and
higher viral replication in the heart of PAmut-infected mice compared to PB2mut- and
Mock-infected animals. Further molecular studies in infected hiPSC-CMs also showed
consistent alterations in ion channel expression and mitochondrial dysfunction, which were
more evident in PAmut-infected cells. Interestingly, YMEL1 has been involved in mitochondria
dynamics, heart failure, maintenance of mitochondrial
structure, and respiratory chain biogenesis, and stresses the relevance of correct
proteostasis for mitochondrial integrity. Accordingly, the M2 protein of influenza virus (a viroprotein)
causes alteration of mitochondrial morphology, dissipation of mitochondrial membrane
potential, and cell death
(reviewed in Refs44,45). Altogether, the data support a heart
mitochondrial damage observed upon human IAV infection (Figure ), consistently with ATP decrease, especially
in the highly pathogenic PAmut virus (Figure ).In the clinic, ventricular arrhythmia leading to sudden cardiac death may be also a fatal
consequence of fulminant myocarditis associated with influenza A infection. In mice, we have not documented
ventricular arrhythmic events in any of the infected groups of mice. Conversely, we have
documented severe bradycardia and conduction abnormalities in one PAmut-infected mouse at
the time of premature death 3 days after infection. However, myocarditis-related ventricular
arrhythmia is a rare phenomenon in infected patients, which may also be the case in mice. In
addition, we did not have the possibility of obtaining continuous ECG recordings under
biosafety level 2+ conditions, which has also affected our ability to record ventricular
arrhythmia. Notwithstanding such different rhythm alterations reported in the clinic, the
ability of the virus to infect cardiac tissue makes it a potential hazard., Here, we report that this is especially relevant for viral strains
of high pathogenicity. Fortunately, there are clinical reports of influenza-induced
fulminant myocarditis successfully treated with intravenous peramivir., Therefore, new studies are warranted to investigate the potential
value of antiviral therapies in cases with heart infection in the clinic.
4.1 Limitations
Biosafety restrictions did not allow performing echocardiography studies in mice
undergoing sequential ECG monitoring. Histopathology analysis did not show immune cell
infiltration at 4-day post-infection, which may be consistent with sequential findings of
viral myocarditis in mice models; with an initial increase in inflammatory cytokines prior
to inflammatory cell infiltration that would be predominantly evident at day 5
post-infection.
Conclusions
Human IAV can infect the heart and cardiac-specific conduction system, which may contribute
to virus-related cardiac complications and premature death in the clinic.
Supplementary material
Supplementary material is
available at Cardiovascular Research online.
Authors’ contributions
J.V., A.N., and A.F. contributed to the design acquisition, analysis, and interpretation of
all viral inoculation and viral growth studies in cell culture and in vivo. N.Z. and C.G.
contributed to the acquisition, analysis, and interpretation of the studies performed in
cell-cultured cardiomyocytes. D.F.-R., J.J., and S.N.N. contributed to the design
acquisition, analysis, and interpretation of the ECG and cardiac imaging data. J.M.-A.-A.
contributed to the analysis of fibrosis and inflammation data. A.F., N.Z., and A.N.
contributed to the design acquisition, analysis, and interpretation of hiPSCs infection.
A.B. and C.P.C., contributed to software development and analysis of ECG and cardiac imaging
data. J.A.N.-A. and A.H. contributed to the design acquisition and analysis of
immunoconfocal microscopy and histology images. D.C., M.D., and J.R.-C. contributed to the
design of cardiac imaging protocols and acquisition of cardiac magnetic resonance images.
A.F., D.P.C., and G.G.-S. contributed to the design acquisition and analysis Purkinje fibres
infection. A.N., J.J., and J.V. contributed to drafting and revising the article. A.F.
supervised the studies. D.F.-R. and A.F. wrote the article.Click here for additional data file.
Authors: Jennifer L Nguyen; Wan Yang; Kazuhiko Ito; Thomas D Matte; Jeffrey Shaman; Patrick L Kinney Journal: JAMA Cardiol Date: 2016-06-01 Impact factor: 14.676
Authors: Daniela Ponce-Balbuena; Guadalupe Guerrero-Serna; Carmen R Valdivia; Ricardo Caballero; F Javier Diez-Guerra; Eric N Jiménez-Vázquez; Rafael J Ramírez; André Monteiro da Rocha; Todd J Herron; Katherine F Campbell; B Cicero Willis; Francisco J Alvarado; Manuel Zarzoso; Kuljeet Kaur; Marta Pérez-Hernández; Marcos Matamoros; Héctor H Valdivia; Eva Delpón; José Jalife Journal: Circ Res Date: 2018-03-07 Impact factor: 17.367
Authors: Ana M Falcón; Rosa M Marión; Thomas Zürcher; Paulino Gómez; Agustín Portela; Amelia Nieto; Juan Ortín Journal: J Virol Date: 2004-04 Impact factor: 5.103
Authors: Yi-Han Lin; Maryann P Platt; Ryan P Gilley; David Brown; Peter H Dube; Yanbao Yu; Norberto Gonzalez-Juarbe Journal: Circ Res Date: 2021-01-27 Impact factor: 17.367
Authors: Adam D Kenney; Stephanie L Aron; Clara Gilbert; Naresh Kumar; Peng Chen; Adrian Eddy; Lizhi Zhang; Ashley Zani; Nahara Vargas-Maldonado; Samuel Speaks; Jeffrey Kawahara; Parker J Denz; Lisa Dorn; Federica Accornero; Jianjie Ma; Hua Zhu; Murugesan V S Rajaram; Chuanxi Cai; Ryan A Langlois; Jacob S Yount Journal: Sci Adv Date: 2022-05-11 Impact factor: 14.957
Authors: Arutha Kulasinghe; Ning Liu; Chin Wee Tan; James Monkman; Jane E Sinclair; Dharmesh D Bhuva; David Godbolt; Liuliu Pan; Andy Nam; Habib Sadeghirad; Kei Sato; Gianluigi Li Bassi; Ken O'Byrne; Camila Hartmann; Anna Flavia Ribeiro Dos Santos Miggiolaro; Gustavo Lenci Marques; Lidia Zytynski Moura; Derek Richard; Mark Adams; Lucia de Noronha; Cristina Pellegrino Baena; Jacky Y Suen; Rakesh Arora; Gabrielle T Belz; Kirsty R Short; Melissa J Davis; Fernando Souza-Fonseca Guimaraes; John F Fraser Journal: Immunology Date: 2022-09-15 Impact factor: 7.215
Authors: Indranil Bhattacharya; Chafik Ghayor; Ana Pérez Dominguez; Franz E Weber Journal: Front Endocrinol (Lausanne) Date: 2020-10-06 Impact factor: 5.555